MAGE-A expression clusters and antineoplastic treatment in head and neck cancer

Hartmann,Stefan; Meyer,Till J.; Brands,Roman  C.; Haubitz,Imme  R.; Linz,Christian; Seher,Axel; Kübler,Alexander  C.; Müller-Richter,Urs  D.A.

doi:10.3892/ijmm.2015.2174

MAGE-A expression clusters and antineoplastic treatment in head and neck cancer

Authors:
- Stefan Hartmann
- Till J. Meyer
- Roman C. Brands
- Imme R. Haubitz
- Christian Linz
- Axel Seher
- Alexander C. Kübler
- Urs D.A. Müller-Richter
View Affiliations

Affiliations: Department of Oral and Maxillofacial Plastic Surgery, University Hospital of Würzburg, D-97070 Würzburg, Germany
Published online on: April 7, 2015 https://doi.org/10.3892/ijmm.2015.2174
Pages: 1675-1682

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The nonsurgical treatment of head and neck squamous cell carcinoma (HNSCC) usually consists of radiation and chemotherapy. In general, the treatment efficacy of chemotherapy in head and neck cancer is limited. Apart from the placenta, testis and fetal keratinocytes, melanoma-associated antigens‑A (MAGE‑A) are only found in malignancies. Even though their molecular role remains unclear, several subgroups have been found to contribute to resistance to different chemotherapeutic agents. In the present study, established human squamous cell carcinoma cell lines were incubated with various concentrations of cisplatin, 5-fluorouracil, paclitaxel, docetaxel, cetuximab and panitumumab for 5, 10, 20 and 40 h. The treatment efficacy was measured dynamically by real-time cell analysis (RTCA). In addition, we determined the expression of all known MAGE‑A subgroups (MAGE‑A1 to MAGE‑A12, excluding pseudogene MAGE‑A7) by reverse transcription quantitative polymerase chain reaction. Of note, one cell line showed only a marginal expression of MAGE‑A antigens, whereas another cell line showed a distinct expression of almost all the MAGE‑A subgroups. The expression pattern varied in the other cell lines. MAGE‑A4 was the most highly expressed of all the subgroups, and MAGE‑A8 could not be detected. With the exception of MAGE‑A6, -A8, -A9 and -A10, the expression levels differed significantly between the cell lines. Factor analysis suggested simplifying the MAGE‑A expression level into two groups. Spearman's rank correlation revealed a significant association between MAGE‑A expression and treatment efficacy for 20.8% (25/120) of the experiments. In 100% of these cases (25/25), Spearman's Rho revealed a positive correlation between clustered MAGE‑A expression and poor treatment efficacy. Our data highlight the fact that higher a MAGE‑A expression correlates with a poorer outcome of antineoplastic treatment. Clustered MAGE‑A expression analysis may help to identify patients who are at a higher risk of antineoplastic treatment failure.

View Figures

View References

1	Gupta S, Kong W, Peng Y, Miao Q and Mackillop WJ: Temporal trends in the incidence and survival of cancers of the upper aerodigestive tract in Ontario and the United States. Int J Cancer. 125:2159–2165. 2009. View Article : Google Scholar : PubMed/NCBI
2	Simpson AJ, Caballero OL, Jungbluth A, Chen YT and Old LJ: Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 5:615–625. 2005. View Article : Google Scholar : PubMed/NCBI
3	van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A and Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 254:1643–1647. 1991. View Article : Google Scholar : PubMed/NCBI
4	Abd-Elsalam EA and Ismaeil NA: Melanoma-associated antigen genes: A new trend to predict the prognosis of breast cancer patients. Med Oncol. 31:2852014. View Article : Google Scholar : PubMed/NCBI
5	Li G, Song P and Zhang B: Expression and significance of MAGE genes in human lung cancer. Zhongguo Fei Ai Za Zhi. 16:308–313. 2013.In Chinese. PubMed/NCBI
6	Dyrskjøt L, Zieger K, Kissow Lildal T, Reinert T, Gruselle O, Coche T, Borre M and Ørntoft TF: Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma. Br J Cancer. 107:116–122. 2012. View Article : Google Scholar : PubMed/NCBI
7	Zhang QM, He SJ, Shen N, Luo B, Fan R, Fu J, Luo GR, Zhou SF, Xiao SW and Xie XX: Overexpression of MAGE-D4 in colorectal cancer is a potentially prognostic biomarker and immunotherapy target. Int J Clin Exp Pathol. 7:3918–3927. 2014.PubMed/NCBI
8	Gu X, Fu M, Ge Z, Zhan F, Ding Y, Ni H, Zhang W, Zhu Y, Tang X, Xiong L, et al: High expression of MAGE-A9 correlates with unfavorable survival in hepatocellular carcinoma. Sci Rep. 4:66252014. View Article : Google Scholar : PubMed/NCBI
9	Laban S, Atanackovic D, Luetkens T, Knecht R, Busch CJ, Freytag M, Spagnoli G, Ritter G, Hoffmann TK, Knuth A, et al: Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer. Int J Cancer. 135:1142–1152. 2014. View Article : Google Scholar : PubMed/NCBI
10	Sahin U, Türeci O, Chen YT, Seitz G, Villena-Heinsen C, Old LJ and Pfreundschuh M: Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: Basis for polyvalent CT vaccine strategies. Int J Cancer. 78:387–389. 1998. View Article : Google Scholar : PubMed/NCBI
11	Krauss E, Rauthe S, Gattenlöhner S, Reuther T, Kochel M, Kriegebaum U, Kübler AC and Müller-Richter UD: MAGE-A antigens in lesions of the oral mucosa. Clin Oral Investig. 15:315–320. 2011. View Article : Google Scholar
12	Han L, Jiang B, Wu H, Zhang S and Lu X: Expression and prognostic value of MAGE-A9 in laryngeal squamous cell carcinoma. Int J Clin Exp Pathol. 7:6734–6742. 2014.PubMed/NCBI
13	Hartmann S, Kriegebaum U, Küchler N, Brands RC, Linz C, Kübler AC and Müller-Richter UD: Correlation of MAGE-A tumor antigens and the efficacy of various chemotherapeutic agents in head and neck carcinoma cells. Clin Oral Investig. 18:189–197. 2014. View Article : Google Scholar
14	Hartmann S, Kriegebaum U, Küchler N, Lessner G, Brands RC, Linz C, Schneider T, Kübler AC and Müller-Richter UD: Efficacy of cetuximab and panitumumab in oral squamous cell carcinoma cell lines: Prognostic value of MAGE-A subgroups for treatment success. J Craniomaxillofac Surg. 41:623–629. 2013. View Article : Google Scholar : PubMed/NCBI
15	Monte M, Simonatto M, Peche LY, Bublik DR, Gobessi S, Pierotti MA, Rodolfo M and Schneider C: MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci USA. 103:11160–11165. 2006. View Article : Google Scholar : PubMed/NCBI
16	Duan Z, Duan Y, Lamendola DE, Yusuf RZ, Naeem R, Penson RT and Seiden MV: Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin Cancer Res. 9:2778–2785. 2003.PubMed/NCBI
17	Liu W, Cheng S, Asa SL and Ezzat S: The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. Cancer Res. 68:8104–8112. 2008. View Article : Google Scholar : PubMed/NCBI
18	Vansteenkiste J, Zielinski M, Linder A, et al: Adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC): Final results of a multi-center, double-blind, randomized, placebocontrolled phase II study evaluating the MAGE-A3 cancer immunotherapeutic. EJC Suppl. 5:3612007. View Article : Google Scholar
19	Heo DS, Snyderman C, Gollin SM, Pan S, Walker E, Deka R, Barnes EL, Johnson JT, Herberman RB and Whiteside TL: Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines. Cancer Res. 49:5167–5175. 1989.PubMed/NCBI
20	Hartmann S, Seher A, Brands RC, Linz C, Lessner G, Böhm H, Kübler AC and Müller-Richter UD: Influence of epidermal growth factor receptor expression on the cetuximab and pani-tumumab response rates of head and neck carcinoma cells. J Craniomaxillofac Surg. 42:1322–1328. 2014. View Article : Google Scholar : PubMed/NCBI
21	Wheeler SE, Shi H, Lin F, Dasari S, Bednash J, Thorne S, Watkins S, Joshi R and Thomas SM: Enhancement of head and neck squamous cell carcinoma proliferation, invasion, and metastasis by tumor-associated fibroblasts in preclinical models. Head Neck. 36:385–392. 2014. View Article : Google Scholar :
22	Yang B, O’Herrin SM, Wu J, Reagan-Shaw S, Ma Y, Bhat KM, Gravekamp C, Setaluri V, Peters N, Hoffmann FM, et al: MAGE-A, mMAGE-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res. 67:9954–9962. 2007. View Article : Google Scholar : PubMed/NCBI
23	Feng Y, Gao J and Yang M: When MAGE meets RING: Insights into biological functions of MAGE proteins. Protein Cell. 2:7–12. 2011. View Article : Google Scholar : PubMed/NCBI
24	Marcar L, Maclaine NJ, Hupp TR and Meek DW: MAGE-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin. Cancer Res. 70:10362–10370. 2010. View Article : Google Scholar : PubMed/NCBI
25	Ries J, Vairaktaris E, Mollaoglu N, Wiltfang J, Neukam FW and Nkenke E: Expression of melanoma-associated antigens in oral squamous cell carcinoma. J Oral Pathol Med. 37:88–93. 2008. View Article : Google Scholar : PubMed/NCBI
26	Bandić D, Juretić A, Sarcević B, Separović V, Kujundzić-Tiljak M, Hudolin T, Spagnoli GC, Cović D and Samija M: Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: Retrospective immunohistochemical study. Croat Med J. 47:32–41. 2006.
27	Sakurai T, Itoh K, Higashitsuji H, Nagao T, Nonoguchi K, Chiba T and Fujita J: A cleaved form of MAGE-A4 binds to Miz-1 and induces apoptosis in human cells. J Biol Chem. 279:15505–15514. 2004. View Article : Google Scholar : PubMed/NCBI
28	Xu X, Tang X, Lu M, Tang Q, Zhang H, Zhu H, Xu N, Zhang D, Xiong L, Mao Y, et al: Overexpression of MAGE-A9 predicts unfavorable outcome in breast cancer. Exp Mol Pathol. 97:579–584. 2014. View Article : Google Scholar : PubMed/NCBI
29	Hatiboglu G, Pritsch M, Macher-Goeppinger S, Zöller M, Huber J, Haferkamp A, Pahernik S, Wagener N and Hohenfellner M: Prognostic value of melanoma-associated antigen A9 in renal cell carcinoma. Scand J Urol. 47:311–322. 2013. View Article : Google Scholar
30	Xia LP, Xu M, Chen Y and Shao WW: Expression of MAGE-A11 in breast cancer tissues and its effects on the proliferation of breast cancer cells. Mol Med Rep. 7:254–258. 2013.
31	Lian Y, Sang M, Ding C, Zhou X, Fan X, Xu Y, Lü W and Shan B: Expressions of MAGE-A10 and MAGE-A11 in breast cancers and their prognostic significance: A retrospective clinical study. J Cancer Res Clin Oncol. 138:519–527. 2012. View Article : Google Scholar